Insight
Comment: How industry unity in femtech can be a catalyst for women’s health innovation
By Sheena D. Franklin, founder of K’ept Health, a women’s focused heath informatics company.
The femtech industry is at a turning point. What started as a niche sector has evolved into a multi-billion-dollar powerhouse addressing critical gaps in women’s health. Yet, despite this rapid growth, femtech founders still face major roadblocks—limited investment, regulatory hurdles, and the lack of comprehensive data needed to drive real change.
For femtech to truly transform women’s health and establish itself as an essential pillar of healthcare innovation, we need to move beyond working in isolation. A more connected, collaborative ecosystem will help shift the perception of femtech from a specialized market to a driving force behind broader healthcare reform.
Breaking silos to build a stronger femtech ecosystem
One of the biggest challenges in femtech today is fragmentation. Companies are making incredible strides in fertility, menopause, chronic disease management, and more—but often in isolation. Without deeper collaboration, we risk redundancy—tackling the same problems separately instead of driving collective progress.
This isn’t just an obstacle—it’s a missed opportunity. Too many femtech founders navigate regulatory hurdles, consumer trust issues, and market education barriers alone, without tapping into the collective knowledge of their peers. The truth is, no single company can solve all the unmet needs in women’s health on its own. But by sharing insights, resources, and lessons learned, founders can accelerate progress—not just for their own companies, but for the entire industry.
Other sectors have successfully made this shift. Fintech, for example, has thrived by forming alliances to drive financial inclusion. Femtech can take a similar approach by fostering open dialogue, creating strategic partnerships, and embracing collaboration as a growth strategy. When femtech companies support one another, the industry moves faster, innovation happens more efficiently, and—most importantly—women get better solutions, sooner.
The power of data collaboration to overcome silos
Breaking down silos is one thing—but real progress happens when companies collaborate on data. Many femtech companies collect valuable user-generated health data, yet without a secure way to share and analyse these insights, the industry misses a huge opportunity to drive systemic change.
Understandably, concerns over competitive advantage and patient trust make data-sharing a tricky subject. But companies that find responsible, privacy-focused ways to collaborate on data will lead the next wave of women’s health innovation.
A prime example is the FemIndex by K’ept Health, which is pioneering responsible data collaboration in women’s health. Using federated machine learning, the FemIndex allows secure data sharing across multiple femtech sectors while protecting user privacy. Instead of working in silos, companies can contribute to and benefit from a diverse, high-quality dataset that strengthens AI models, accelerates drug discovery and improves precision medicine.
Industry-wide collaboration is also taking shape through initiatives like The Wonder Woman Collective, which unites femtech companies to streamline specialty care, close coverage gaps, and reduce costs for conditions like migraines, hypothyroidism, and PCOS. This collective is also working to engage payers, conduct cost-saving studies, and advocate for increased federal investment in women’s health. As part of the initiative, participating companies will share anonymized medical records to support R&D efforts.
By combining specialised care platforms with advanced data-sharing infrastructures, we can create a network-driven approach that strengthens femtech’s ability to scale while accelerating progress across the entire industry.
Strength in numbers: Industry standards, policy, and investment
Beyond technology and data, a united femtech sector can wield more influence in shaping policy, investment trends, and regulatory frameworks.
Setting industry standards is key to solidifying femtech as a major force in healthcare. By defining best practices for women’s health technologies, femtech leaders can ensure innovations are safe, effective, and widely trusted. Standardized guidelines also make it easier to secure regulatory approval, attract investors, and drive adoption.
A unified femtech industry can also push for better reimbursement models, clear clinical validation pathways, and stronger partnerships with healthcare providers. Working together, femtech leaders can advocate for insurance coverage that makes solutions more affordable and accessible. Deeper collaboration with hospitals and health systems will drive mainstream adoption and bridge the gaps in traditional care models—positioning femtech as an integral part of modern healthcare.
A united femtech future
Other industries have shown that competitors can work together to drive collective success. In the automotive sector, manufacturers collaborate on safety standards and emissions regulations, raising industry-wide standards while still competing in the market. In pharma, companies share research data to accelerate drug discovery, recognizing that advancing healthcare benefits everyone.
Femtech must do the same. The question is no longer whether should we work together—it’s how quickly we can embrace this shift. The future of femtech depends on our willingness to share knowledge, advocate collectively, and build a unified front that cements femtech as a critical part of the healthcare landscape.
Now is the time to move forward—together.
Sheena D. Franklin is founder of K’ept Health, a women’s focused heath informatics company. He other roles include chair of the Women’s Health Working Group for the Consumer Technology Association, where she leads standards creation for women’s health technology, and a trusted advisor to the American Medical Association and the Aspen Institute.
Black women in the UK want clearer, more accessible breast cancer screening information, research has found.
The study looked at why Black African and Black Caribbean women are less likely than white women to attend breast screening.
Researchers at the University of Surrey held focus groups and interviews with 47 Black African and Black Caribbean women aged 50 to 71.
Women in this age group are routinely invited for NHS breast screening.
The researchers said only 45 per cent of Black women attend screening, compared with 63 per cent of white women.
Anietie Aliu, lead author, postgraduate researcher at the University of Surrey and registered nurse, said: “Diagnosing breast cancer early can dramatically improve a person’s chance of survival.
“Breast cancer screening plays an important role in this by identifying the cancer and ensuring a person receives speedy treatment.
“Despite the importance of screening, Black women are less likely to attend appointments than white females.
“This puts them at risk of a potential cancer being diagnosed late and spreading to other areas of the body. We need to understand what is preventing Black women from attending these appointments and help identify ways to remove such barriers.”
The study found a need to increase awareness of breast cancer screening, especially among women less familiar with the service.
Some women, particularly those born outside the UK, knew little about breast screening before receiving their first invitation.
Others questioned why they needed screening when they had no symptoms.
The importance of trusted conversations was also identified.
Researchers found that some Black women expected their GPs to speak to them about breast screening, particularly before they reached screening age.
Although NHS breast screening is organised through national screening services, researchers said GPs often have established relationships with patients and may be well placed to offer brief advice on preventive care, including breast screening.
Participants called for stronger links between GP practices, breast screening services and Black community champions.
They said this could help women receive trusted information, ask questions and feel reassured.
Faith and religious beliefs also shaped decisions for some women.
Some Black African Christian women said illness, including cancer, was not permitted by God in their bodies, while others saw screening as a personal choice that did not conflict with Christian faith.
Muslim women highlighted the importance of being able to state their religion on medical appointment forms to help ensure they were seen by a female mammographer.
A mammographer is a healthcare professional trained to carry out breast screening scans.
Aliu added: “Breast screening can save lives, but our findings show that attendance is shaped by multiple factors, not just awareness, although awareness remains important.
“Women need relatable screening information, reassurance, flexible appointments and services that are accessible within their communities.
“Many felt that invitation letters were too formal, and that leaflets and media imagery did not reflect them, making it harder to relate to screening.”
Dr Afrodita Marcu, senior research fellow at the University of Surrey and member of the research team, said: “We need a more collaborative approach, where primary care, screening services and community voices work together to support women before, during and after the invitation.”
The researchers said future breast screening interventions should be designed with Black women, rather than for them.
They said user-friendly and culturally relevant resources, developed with communities, healthcare professionals and screening services, could improve understanding, reduce fear and make breast screening feel more accessible and reassuring.
Dr Robert Kerrison, associate professor of cancer care at the University of Surrey, said: “There is no question that breast screening can be lifesaving, but we need to make it easier for women to understand, access and feel reassured by the programme.
“This means improving communication, addressing practical barriers and making sure healthcare professionals and community partners are supported to provide clear and trusted information.”
The team has also explored healthcare professionals’ perspectives and worked with stakeholders to develop user-friendly materials with Black women.
Researchers said this co-designed approach could help ensure breast screening messages are culturally relevant, practical and shaped by the people they are intended to support.
Insight
“Women’s voices should be heard and pain should never be ignored,” says Wales’s first Women’s Health Minister
Women’s pain should not simply be endured, Wales’s first women’s health minister has said.
Delyth Jewell said she was determined to tackle the normalisation of pain in women’s healthcare and ensure women’s voices are listened to.
Speaking during a Women’s Health Summit at the Temple of Peace on Thursday, July 16, she said: “For too long, women’s health has been treated as an afterthought. No woman should be afraid to speak up about pain or things that don’t feel right.
“Women should be believed about their bodies, and I am determined to change the culture that has let too many women down.”
She added: “Women’s voices helped create the Women’s Health Plan. Now we’re making sure those voices continue to shape what comes next.”
The summit brought together clinicians, researchers and women with lived experience to tackle the normalisation of pain in healthcare and identify how women’s voices can better shape NHS services.
Lived experience means insight from people who have personally gone through a health issue or used healthcare services.
The event focused on pain linked to clinical procedures and long-term health conditions, drawing on research evidence, clinical expertise and women’s personal experiences.
Following the summit, minimum standards for service user engagement will be drafted to ensure women’s voices continue to influence the delivery and future priorities of the Women’s Health Plan.
Service user engagement means involving people who use health services in decisions about how care is designed, delivered and improved.
Work will also begin to refresh and strengthen the plan, including gathering feedback directly from women across Wales.
The NHS Wales Women’s Health Plan was developed after discovery work in 2022, when women across Wales shared their experiences of healthcare.
Many said they had not felt listened to, had symptoms dismissed or had lived with pain for years before receiving a diagnosis.
Hosted by Amanda Ducach, CEO, and Morgan Rose, chief science officer, EmaEQ
Healthcare companies have spent the last two years hearing the same advice: get AI into your product. Few have been told what that actually takes.
Most default to the fastest option. Plug in a general-purpose model, wrap it in a chat window, and call the box checked. It looks like progress on a roadmap slide. It rarely holds up once a real patient is on the other end of it.
We’ve spent years building AI specifically for healthcare, and the lesson that keeps repeating itself is simple: accuracy is not the same thing as trust, and trust isn’t something you bolt on after launch. It has to be part of how the system is built from the first line of code, not a feature added once regulators or users start asking questions.
That distinction is the whole reason clinical accuracy gets treated as a checkbox instead of a discipline. A model can sound confident and still be wrong in ways that matter enormously in a health context.
Knowing the difference, and building for it deliberately, is what separates AI that’s genuinely safe for care from AI that’s simply fast to ship.
On July 20th, we’re hosting a live conversation about exactly this: what companies should be paying attention to before they choose an AI to build with, what clinical accuracy really requires, and the pillars we hold every AI system to before it gets anywhere near a patient’s care.
The Healthcare AI Playbook Webinar: July 20th, 1:30-2pm EST, live on LinkedIn.
Register here: https://www.linkedin.com/events/7482643171823509504?viewAsMember=true
If your team is building anywhere near healthcare, or evaluating what’s already in your product, this is the conversation we think the industry needs right now.
Diagnosis2 weeks agoTwo “gamechanger” tests set to speed up endometriosis diagnosis on the NHS
Insight2 weeks agoWomen with PMOS should have annual NHS checks, new guidance says
News3 days agoNew menopause drug approved for use by NHS in Scotland
Cancer1 week agoThousands of women could avoid painful cancer exam with new AI blood test
Entrepreneur1 week agoApplications open for the third W Accelerate with Merck KGaA and M Ventures
Fertility2 weeks agoOlder women face lower chance of fertility treatment working, even with donor eggs, study finds
News1 week agoWe built Ema like a nurse: Here’s why that matters
News2 weeks agoExperts call for regulation of toxic period product chemicals